Bukwang Pharm Co Ltd
KRX:003000
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bukwang Pharm Co Ltd
Operating Expenses
Bukwang Pharm Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bukwang Pharm Co Ltd
KRX:003000
|
Operating Expenses
-₩72.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Expenses
-₩625.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Expenses
-₩459.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Expenses
-₩626.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Expenses
-₩100.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Operating Expenses
-₩31.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Bukwang Pharm Co Ltd
Glance View
Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.
See Also
What is Bukwang Pharm Co Ltd's Operating Expenses?
Operating Expenses
-72.5B
KRW
Based on the financial report for Sep 30, 2025, Bukwang Pharm Co Ltd's Operating Expenses amounts to -72.5B KRW.
What is Bukwang Pharm Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-2%
Over the last year, the Operating Expenses growth was 4%. The average annual Operating Expenses growth rates for Bukwang Pharm Co Ltd have been 1% over the past three years , -1% over the past five years , and -2% over the past ten years .
